Top 20 Healthcare & Life Sciences PEF 2025

This report forms part of the Ranking News Capital Ranking series, which evaluates private equity firms and investment platforms across global capital markets.

Healthcare and life sciences private equity has become one of the most strategically important segments of global private markets. As healthcare systems face demographic pressure, regulatory complexity, technological transformation, and rising demand for specialized services, private equity firms with deep healthcare expertise have become influential investors across healthcare services, pharmaceuticals, medtech, life sciences tools, diagnostics, and healthcare IT.

Unlike generalist private equity, healthcare investing requires specialized underwriting capabilities. Investors must evaluate reimbursement systems, regulatory exposure, clinical workflows, provider networks, payer dynamics, product approval pathways, and long-term demand drivers. This complexity creates meaningful differentiation between firms with genuine healthcare specialization and those that participate opportunistically.

The sector continues to attract institutional capital because healthcare combines structural demand with opportunities for operational improvement, consolidation, and technology-enabled transformation. At the same time, increased public scrutiny and regulatory attention require investors to demonstrate discipline, responsible ownership, and sector-specific judgment.

This ranking identifies private equity firms whose healthcare and life sciences investment platforms demonstrate sustained institutional relevance, sector expertise, transaction execution capabilities, and influence within global private markets.

Market Overview

Healthcare private equity remains active across multiple subsectors, including provider services, specialty care, healthcare technology, outsourced pharmaceutical services, medtech, diagnostics, contract research, and life sciences tools. The sector’s breadth allows firms to pursue different risk-return profiles, ranging from stable healthcare services platforms to innovation-driven life sciences investments.

Healthcare services have historically been a major area of private equity deployment, particularly in fragmented provider markets where consolidation and operational improvement can create scale advantages. Specialty physician practices, dental services, behavioral health, veterinary care, and outpatient care platforms have all attracted significant investment.

Life sciences investing requires a different set of capabilities. Firms active in pharmaceutical services, medtech, diagnostics, and life sciences tools must understand product development cycles, regulatory pathways, scientific differentiation, and customer adoption dynamics.

Healthcare IT and digital health continue to gain importance as providers, payers, and life sciences companies invest in workflow automation, data infrastructure, revenue cycle management, and patient engagement solutions. Firms with both healthcare and software expertise are increasingly well positioned in this segment.

Industry Trend — 2025

In 2025, healthcare and life sciences private equity is increasingly shaped by regulatory discipline, operational quality, and subsector specialization. Investors are moving away from purely financial consolidation strategies and placing greater emphasis on sustainable operating models, clinical quality, compliance infrastructure, and long-term value creation.

Healthcare services remain attractive, but scrutiny around staffing, billing practices, patient outcomes, and ownership models has increased. As a result, leading private equity firms are differentiating themselves through more sophisticated governance, compliance, and operating frameworks.

Life sciences and pharmaceutical services continue to attract capital due to long-term demand for drug development support, diagnostics, research tools, and outsourced commercialization infrastructure. These areas often provide exposure to innovation without requiring direct early-stage drug development risk.

Healthcare technology remains a major theme, particularly where software can reduce administrative burden, improve workflow efficiency, or support data-driven decision-making. Revenue cycle management, clinical workflow software, payer technology, and healthcare data platforms remain key areas of investment interest.

As the sector evolves, firms with specialized healthcare teams, regulatory understanding, operating depth, and disciplined underwriting are expected to maintain leadership positions.

Methodology — Core Eligibility Criteria

To ensure structural consistency within the category, firms considered for this ranking were evaluated based on the following eligibility conditions:

• Operates as a private equity firm or dedicated private equity platform
• Maintains a significant focus on healthcare, life sciences, or healthcare technology
• Demonstrates experience in control, growth, or structured private equity investments
• Shows sector expertise across healthcare services, pharma services, medtech, diagnostics, life sciences tools, or healthcare IT
• Maintains institutional relevance within healthcare private capital markets

Pure venture capital firms, public-market healthcare investors, and generalist private equity firms without meaningful healthcare specialization are generally excluded.

Methodology — Ranking Factors

Firms included in the ranking were evaluated using a combination of qualitative and structural considerations rather than short-term fund performance metrics. Key factors considered include:

• Depth of healthcare and life sciences sector expertise
• Track record in healthcare and life sciences investments
• Ability to execute platform-building and consolidation strategies
• Operational value creation capabilities within regulated healthcare markets
• Institutional scale and capital deployment capacity
• Reputation among healthcare executives, founders, intermediaries, and institutional investors
• Stability and longevity of the investment platform

The objective of the ranking is to identify firms whose healthcare and life sciences private equity platforms maintain sustained relevance within global private capital markets.

The Ranking News Top 20 Healthcare & Life Sciences Private Equity Firms 2025 ranking evaluates leading private equity firms focused on healthcare and life sciences markets.

The ranking universe consisted of approximately 75 healthcare and life sciences-focused private equity firms, from which 20 institutions were selected for inclusion.

Tier classifications reflect relative institutional positioning within the healthcare and life sciences private equity ecosystem and do not represent investment performance rankings.

---

Tier I — Leading Healthcare & Life Sciences Private Equity Platforms

Warburg Pincus

• Headquarters: New York, United States
• Founded: 1966

Warburg Pincus is one of the most established global private equity firms with a long-standing presence in healthcare and life sciences investing. The firm has invested across healthcare services, healthcare technology, pharmaceuticals, diagnostics, and life sciences-related businesses, combining growth capital flexibility with institutional private equity discipline.

Its healthcare strategy benefits from a global platform and the ability to support companies across different stages of development. Warburg Pincus often backs businesses with scalable models, strong management teams, and significant market expansion potential.

The firm’s experience across both mature and emerging healthcare markets gives it a broad perspective on sector evolution. Its ability to combine growth orientation, global reach, and healthcare specialization supports its position as a leading platform in healthcare and life sciences private equity.

TPG Healthcare

• Headquarters: Fort Worth / San Francisco, United States
• Founded: 1992

TPG has developed a significant healthcare investment presence across healthcare services, life sciences, healthcare technology, and related sectors. The firm’s healthcare activity is supported by its broader global private equity platform, allowing it to deploy capital across large-scale control investments, growth opportunities, and thematic healthcare strategies.

TPG’s healthcare approach emphasizes transformation, scale, and operational improvement. The firm often targets businesses positioned around long-term demand trends, including care delivery, pharmaceutical services, medtech, and digital health infrastructure.

Its global resources and experience in complex transactions allow TPG to support portfolio companies through expansion, strategic repositioning, and operational development. The firm’s sustained commitment to healthcare markets reinforces its role as a leading healthcare private equity participant.

Bain Capital Healthcare

• Headquarters: Boston, United States
• Founded: 1984

Bain Capital is a major global private equity platform with a strong healthcare investment practice. The firm invests across healthcare services, life sciences, medtech, healthcare IT, and pharmaceutical-related businesses, leveraging analytical depth and operational resources to support value creation.

Bain Capital’s healthcare strategy benefits from its broader investment infrastructure and consulting-influenced approach to underwriting and portfolio development. The firm often works closely with management teams to improve commercial strategy, operational efficiency, and organizational scalability.

Its ability to evaluate healthcare businesses through both financial and operational lenses supports disciplined investment execution. Bain Capital’s combination of global scale, healthcare sector expertise, and structured value creation capabilities places it among the leading healthcare and life sciences private equity firms.

Welsh, Carson, Anderson & Stowe (WCAS)

• Headquarters: New York, United States
• Founded: 1979

Welsh, Carson, Anderson & Stowe is one of the most prominent healthcare-focused private equity firms in the United States, with a long history of investing in healthcare services and technology-enabled healthcare businesses. The firm has built deep expertise in provider services, payer services, healthcare IT, and outsourced healthcare infrastructure.

WCAS is particularly known for platform-building strategies in fragmented healthcare markets. The firm frequently partners with management teams to scale businesses through organic growth, add-on acquisitions, and operational development.

Its long-standing specialization gives WCAS strong relationships across healthcare executives, operators, and intermediaries. The firm’s sustained focus on healthcare and technology services supports its position as a benchmark platform within healthcare private equity.

GTCR Healthcare

• Headquarters: Chicago, United States
• Founded: 1980

GTCR is a private equity firm with a strong healthcare investment practice, particularly in healthcare services, pharmaceutical services, medical products, and technology-enabled healthcare businesses. The firm is known for its executive partnership model, often backing experienced management teams to build scalable platforms.

In healthcare, GTCR focuses on sectors where operational execution, market fragmentation, and strategic consolidation can create long-term value. The firm’s approach frequently involves identifying attractive subsectors, partnering with management leaders, and pursuing platform acquisitions.

Its disciplined investment process and hands-on value creation orientation have contributed to a strong reputation in healthcare private equity. GTCR’s combination of sector knowledge, leadership partnerships, and platform-building experience supports its Tier I positioning.

---

Tier II — Established Healthcare & Life Sciences Private Equity Firms

(Alphabetical order)

Avista Capital Partners

• Headquarters: New York, United States
• Founded: 2005

Avista Capital Partners is a private equity firm with a strong focus on healthcare and life sciences-related businesses. The firm invests across pharmaceuticals, medical products, healthcare services, and outsourced healthcare infrastructure, often targeting companies with defensible market positions and opportunities for strategic growth.

Avista’s healthcare orientation allows it to evaluate businesses within regulated and technically complex markets. The firm typically supports portfolio companies through operational improvement, product expansion, and strategic initiatives that enhance long-term competitiveness.

Its focused investment approach and experience across multiple healthcare subsectors position Avista as a recognized participant in healthcare private equity. The firm’s ability to combine sector specialization with private equity execution discipline supports its role within the broader healthcare investment ecosystem.

BPEA EQT Healthcare

• Headquarters: Hong Kong / Stockholm
• Founded: 1997

BPEA EQT has developed a significant healthcare investment presence across Asia and global markets, supported by EQT’s broader private equity platform. The firm invests across healthcare services, pharmaceuticals, medical technology, and related sectors, often targeting businesses positioned to benefit from rising healthcare demand and market modernization.

Its regional expertise is particularly important in Asian healthcare markets, where demographic change, income growth, and healthcare infrastructure development continue to create investment opportunities. BPEA EQT combines local market knowledge with institutional private equity discipline.

The platform’s integration with EQT strengthens its global capabilities, sector resources, and operational support. Its healthcare activity across growth markets and established economies supports its inclusion among established healthcare private equity firms.

Charlesbank Capital Partners

• Headquarters: Boston, United States
• Founded: 1998

Charlesbank Capital Partners is a middle-market private equity firm with meaningful healthcare investment activity across healthcare services, healthcare technology, and related business services. The firm typically focuses on companies where operational improvement, strategic repositioning, and management partnership can support value creation.

In healthcare, Charlesbank’s approach emphasizes disciplined underwriting and careful assessment of regulatory, reimbursement, and market dynamics. The firm often targets businesses with strong customer relationships, recurring demand, and opportunities for professionalization or expansion.

Its middle-market focus allows Charlesbank to access opportunities that may be less competitive than large-cap healthcare transactions. The firm’s combination of healthcare experience, operational orientation, and flexible investment approach supports its position within the healthcare private equity landscape.

Frazier Healthcare Partners

• Headquarters: Seattle, United States
• Founded: 1991

Frazier Healthcare Partners is a healthcare-focused investment firm with activity across healthcare services, life sciences, and growth-oriented healthcare businesses. The firm has built a strong reputation through its dedicated focus on healthcare and its ability to operate across different segments of the industry.

Frazier’s healthcare services strategy emphasizes scalable platforms, operational improvement, and management partnerships. Its life sciences activity provides exposure to innovation-driven healthcare markets, supported by scientific and commercial expertise.

The firm’s sector focus gives it specialized insight into healthcare market dynamics, regulatory considerations, and growth opportunities. Frazier’s long-standing healthcare orientation and diversified subsector experience support its recognition as an established healthcare and life sciences private equity platform.

GHO Capital

• Headquarters: London, United Kingdom
• Founded: 2014

GHO Capital is a European private equity firm focused exclusively on healthcare. The firm invests across healthcare services, life sciences tools, pharmaceutical services, medtech, diagnostics, and healthcare technology, targeting businesses positioned for international growth and sector transformation.

GHO’s dedicated healthcare specialization differentiates it from broader private equity platforms. The firm combines investment expertise with sector-specific knowledge, allowing it to evaluate complex healthcare businesses and support portfolio companies through expansion, operational development, and strategic repositioning.

Its European base and global healthcare perspective provide access to specialized opportunities across healthcare markets. GHO’s focused identity and growing institutional relevance support its role as an established healthcare private equity firm.

Gryphon Investors Healthcare

• Headquarters: San Francisco, United States
• Founded: 1995

Gryphon Investors is a middle-market private equity firm with notable healthcare investment activity, particularly in healthcare services and healthcare-related business services. The firm targets companies where operational improvement, professionalization, and strategic growth can create meaningful value.

Gryphon’s healthcare investments often focus on fragmented markets with opportunities for platform formation and add-on acquisitions. The firm works closely with management teams to improve systems, expand service offerings, and strengthen organizational infrastructure.

Its middle-market orientation allows it to pursue businesses with strong growth potential before they reach large-cap institutional ownership. Gryphon’s healthcare experience and hands-on operating approach support its recognition within the healthcare private equity sector.

Linden Capital Partners

• Headquarters: Chicago, United States
• Founded: 2004

Linden Capital Partners is a healthcare-focused private equity firm investing across healthcare services, medical products, healthcare IT, and related sectors. The firm’s exclusive focus on healthcare provides a clear sector identity and supports differentiated sourcing and underwriting capabilities.

Linden often targets companies with strong market positions, scalable business models, and opportunities for growth through operational improvement or acquisition-driven expansion. The firm partners closely with management teams to support strategic initiatives and long-term development.

Its dedicated healthcare approach allows Linden to build deep relationships across industry executives, advisors, and operating partners. The firm’s specialization and consistent activity within healthcare private equity support its position as an established platform in the sector.

New Mountain Capital Healthcare

• Headquarters: New York, United States
• Founded: 1999

New Mountain Capital is a private equity firm with significant healthcare investment activity across healthcare services, life sciences services, and healthcare technology. The firm emphasizes defensive growth sectors and business models supported by long-term structural demand.

In healthcare, New Mountain often targets companies that benefit from secular growth, recurring demand, and opportunities for operational enhancement. The firm’s approach focuses on building durable businesses through management partnership, strategic investment, and expansion initiatives.

Its broader investment philosophy emphasizes business quality, industry growth, and operational value creation. New Mountain’s healthcare experience and disciplined approach support its recognition as an established healthcare private equity participant.

RoundTable Healthcare Partners

• Headquarters: Lake Forest, United States
• Founded: 2001

RoundTable Healthcare Partners is a private equity firm focused on healthcare products, services, and related sectors. The firm invests in businesses across medical products, pharmaceuticals, outsourced services, and healthcare distribution, with an emphasis on companies that serve critical healthcare markets.

RoundTable’s specialized healthcare focus allows it to evaluate businesses with technical, regulatory, and operational complexity. The firm often supports portfolio companies through strategic growth initiatives, operational improvements, and acquisition-led expansion.

Its sector-specific orientation and middle-market focus provide a differentiated position within healthcare private equity. RoundTable’s experience in healthcare products and services supports its recognition as an established firm in the category.

Water Street Healthcare Partners

• Headquarters: Chicago, United States
• Founded: 2005

Water Street Healthcare Partners is a healthcare-focused private equity firm investing in healthcare services, medical products, diagnostics, pharmaceutical services, and healthcare distribution. The firm partners with companies seeking capital, strategic guidance, and operational support to expand within healthcare markets.

Water Street’s investment approach emphasizes sector expertise and collaboration with experienced healthcare executives. The firm often targets businesses with strong customer relationships, specialized capabilities, and opportunities for growth through product expansion or market consolidation.

Its exclusive healthcare focus gives it a clear identity within private equity. Water Street’s experience across multiple healthcare subsectors and its operating-oriented approach support its position as an established healthcare private equity platform.

---

Tier III — Recognized Healthcare & Life Sciences Private Equity Firms

(Alphabetical order)

• ArchiMed
• Arsenal Capital Partners
• Bourne Partners
• Great Point Partners
• Shore Capital Partners

---

Remarks

Healthcare and life sciences private equity remains one of the most complex and strategically important areas of global private markets. The sector combines long-term demand growth with regulatory complexity, scientific innovation, and operational execution challenges.

The firms recognized in this ranking represent platforms with demonstrated expertise in evaluating, acquiring, scaling, and transforming healthcare and life sciences businesses. As healthcare markets continue to evolve, sector specialization, compliance discipline, and operational quality are becoming increasingly important differentiators.

Tier classification reflects relative institutional positioning within the healthcare and life sciences private equity segment and does not represent investment performance rankings.

---

Organizations included in this ranking may request information regarding authorized use of the Ranking News designation for marketing and communications purposes.

Recognition

Organizations included in the Top 20 Healthcare & Life Sciences PEF 2025 ranking may request information regarding authorized use of the Ranking News designation badge for marketing and communications purposes.

Recognized institutions may reference the designation in:

• corporate websites
• investor communications
• marketing materials
• client presentations

Licensing inquiries:
[email protected]